Fundz

Hepion Pharmaceuticals reported raising $2.9 Million in an initial SEC Form D filing, from an offering of $2.9 Million

PUBLIC · HEPAJul 24, 2024

Amount Raised

$2.9 Million

$2.9 Million sold, per SEC Form D (first sale Jul 19, 2024)

Round Type

Venture

Red BankBiotechnology

Quick answer

Hepion Pharmaceuticals raised $2.9 Million in a funding round, dated July 19, 2024. Hepion Pharmaceuticals is based in Red Bank, New Jersey, United States.

How much did Hepion Pharmaceuticals raise?
Hepion Pharmaceuticals raised $2.9 Million in a funding round on July 19, 2024.
What does Hepion Pharmaceuticals do?
Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease.
Where is Hepion Pharmaceuticals based and how big is it?
Hepion Pharmaceuticals is based in Red Bank, New Jersey, United States. Fundz records about 22 employees.
Who are the decision-makers at Hepion Pharmaceuticals?
Fundz holds 1 contact at Hepion Pharmaceuticals, including the SVP Clinical Pharmacology. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Hepion Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • RevolKa raised $1.7M (Series A) on August 30, 2024.
  • Okami Medical raised $19M on August 30, 2024.
  • Pulmotect raised $10M on August 30, 2024.
  • Anuncia Medical raised $11M on August 30, 2024.
  • Ordaos raised $3.1M (Seed) on August 29, 2024.
  • Ensysce Biosciences raised $5.1M on August 29, 2024.

Who to call at Hepion Pharmaceuticals, and when

A new round usually means Hepion Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Hepion Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hepion Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hepion Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Hepion Pharmaceuticals

Location

Red Bank, New Jersey, United States

About

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Hepion Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPatrick M., SVP Clinical Pharmacology hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Hepion Pharmaceuticals's next move

See what Strategic adds

Hepion Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.